10,690 reports of this reaction
5.1% of all TADALAFIL reports
#2 most reported adverse reaction
HEADACHE is the #2 most commonly reported adverse reaction for TADALAFIL, manufactured by United Therapeutics Corporation. There are 10,690 FDA adverse event reports linking TADALAFIL to HEADACHE. This represents approximately 5.1% of all 207,750 adverse event reports for this drug.
TADALAFIL has an overall safety score of 85 out of 100. Patients taking TADALAFIL who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among TADALAFIL users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for TADALAFIL:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 10,690 FDA reports for TADALAFIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 5.1% of all adverse event reports for TADALAFIL, making it one of the most commonly reported side effect.
If you experience headache while taking TADALAFIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.